Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 276 participants.

Also called NCT01365507

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 276 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01365507
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Malaysia, Mexico, Puerto Rico, South Korea, Thailand, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01365507. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2015-11-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
Acronym
BOOST™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01365507
Content hash
14972541cfcece8166de581b381c939739868c5130ad666161f38a2f56a22f55